🏛️ Verified NIH Record • Updated 2026-04-27
Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations (NCT07275359)
🟡 Not Yet Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Duke University
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to investigate the safety and tolerability of Metformin and how it changes blood markers associated with aging in persons who have chronic obstructive pulmonary disease (COPD) who do not have diabetes.
Who can join: Review the eligibility criteria below.
Location: Duke Asthma, Allergy, and Airway Center — Durham, North Carolina
Age range: 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Duke Asthma, Allergy, and Airway Center — Durham, North Carolina
📞 Contact the Study Coordinator
Phone: (919) 684-8111
Email: christopher.mosher@duke.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Obstructive Pulmonary Disease (COPD)
- Laying the Foundation for Building a Resilient KPNC Community in the Face of Worsening Air Quality Due to Wildfire Smoke — Pleasanton, California
- A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease — Birmingham, Alabama
- WearME-Pro Phase II: Remote Use Usability and Longitudinal Validation Study (Patch Form Factor). — Baltimore, Maryland
- Multi-Center Clean Air Randomized Controlled Trial in COPD — Birmingham, Alabama
- To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment — Phoenix, Arizona
Explore by condition: All Chronic Obstructive Pulmonary Disease (COPD) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.